Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?
Moderna (MRNA) will rejoin the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery. The company's market value, now $78.44 billion, qualified it for inclusion after a 571.42% stock rise over twelve months. Despite this, Moderna's financials show negative margins and cash flow, with revenue growth stagnant. The stock trades at $196, with a price-to-sales ratio of 35.21 and short interest at 10.06% of the float.
How this was made
The 30-second read
Why it matters
The re‑entry is a fresh catalyst that can attract passive inflows and improve visibility, potentially supporting the stock price in the short term.
Market read
The news is a primary corporate event that may affect index‑linked funds and biotech sector sentiment.
What to watch
The company's negative margins and cash burn remain concerns that could limit long-term upside despite index inclusion.
Background
Moderna was removed from the Nasdaq-100 in Dec 2024 after its market cap fell below the threshold. A 571% price rally over the past year restored its market cap to $78.44B, qualifying it for re‑entry.
Ticker impact
Nasdaq announced Moderna will rejoin the Nasdaq-100, replacing Warner Bros. Discovery.
likely upward pressure as passive funds add the stock to portfolios
Index membership drives buying from ETFs tracking the Nasdaq-100, creating a floor for the share price.
Market effects
Other biotech stocks may see relative outperformance as investors rotate into the newly added Nasdaq-100 component.
US markets may see a modest lift in the Nasdaq-100 index level.
Limited to US equity markets; no direct global effect.
Counterpoint
If the index inclusion is already priced in, the stock could face short-covering volatility without sustained upside.
Key entities
- companyModerna, Inc.
Biotech firm rejoining the Nasdaq-100.
- companyWarner Bros. Discovery
Company being replaced in the Nasdaq-100.
